Yuichi Kibe

Yuichi Kibe

Auto-generated profile, based on publicly available information

Yuichi Kibe

Yuichi Kibe, MD, Department of Radiation Oncology, JR Tokyo General Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Acta Oncologica
Verified
Journal Article
Closed access
YKYuichi Kibe
Yuichi Kibe
ATAtsuya Takeda
Atsuya Takeda
YTYuichiro Tsurugai
Yuichiro Tsurugai
TETakahisa Eriguchi
Takahisa Eriguchi
Background: To clarify local control by salvage stereotactic body radiotherapy (SBRT) for recurrent/residual hepatocellular carcinoma (HCC) compared with initial definitive SBRT for local treatment-naïve HCC. Material and methods: We retrospectively investigated HCC patients that received SBRT between July 2005 and December 2017. We classified HCC tumors as the initial definitive SBRT group (Arm-1; initial definitive SBRT, Arm-2; initial definitive planned SBRT following transarterial chemoembolization (TACE)) and salvage SBRT group (Arm-3; salvage SBRT for recurrent/residual tumors after TACE, Arm-4; salvage SBRT for recurrent/residual tumors after radiofrequency ablation (RFA), Arm-5; salvage SBRT for recurrent/residual other than Arm-3 or Arm-4). Local control was evaluated by mRECIST. Results: We reviewed 389 HCC tumors of 323 patients treated by 35–40 Gy/5 fr. The median follow-up time for local recurrence of tumors was 34.8 months (range, 6.5–99.2). The cumulative local recurrence rates at 3 years of Arm-1–5 were 1.4% (95% CI, 0.3–4.4%), 5.0% (95% CI, 1.6–11.5%), 12.4% (95% CI, 5.7–21.9%), 14.8% (95% CI, 3.3–34.3%) and 7.3% (95% CI, 1.9–18.0%), respectively. The cumulative local recurrence rates at 3 years of initial definitive treatment and salvage treatment groups were 2.8% (95% CI, 1.1–5.6%) and 11.1% (95% CI, 6.3–17.3%), respectively (p=.004). On multivariate analysis, salvage treatment and the tumor diameter were significant risk factors of local recurrence (p = .02, p < .001 respectively). Estimated overall survival at 3 years for all patients in initial definitive treatment and salvage treatment groups were 71.5% (95% CI, 63.4–78.1%) and 66.1% (95% CI, 56.4–74.2%), respectively (p = .20). No treatment-related death caused by SBRT was observed. Conclusions: This analysis showed local control of salvage SBRT for recurrent/residual HCC was significantly worse than that of initial definitive SBRT for local treatment-naïve HCC. However, local control of salvage SBRT was relatively good, and salvage SBRT is one of the favorable treatment options for recurrent/residual HCC.

17 November 2021 in Acta Oncologica
Verified
Journal Article
Closed access
YKYuichi Kibe
Yuichi Kibe
ATAtsuya Takeda
Atsuya Takeda
YTYuichiro Tsurugai
Yuichiro Tsurugai
TETakahisa Eriguchi
Takahisa Eriguchi
YOYohei Oku
Yohei Oku
NNNaoki Nakamura
Naoki Nakamura
The feasibility of marker-less stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) has not yet been established, and, thus, was examined in the present study.We retrospectively...

6 June 2025 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYuichi Kibe
Yuichi Kibe
NNNaoki Nakamura
Naoki Nakamura